NCT04019873 - 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor | Biotech Hunter

Enrollment

774

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

April 14, 2023

Study Completion Date

December 5, 2023

Conditions

HIV Infections

Interventions

DRUG

Dolutegravir (DTG)

DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.

DRUG

Lamivudine (3TC)

3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.

DRUG

Rilpivirine (RPV)

RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.

Trial Locations (1)

GSK Investigational Site, Barcelona